Literature DB >> 12127669

The nature of the autonomic dysfunction in multiple system atrophy.

Samir M Parikh1, André Diedrich, Italo Biaggioni, David Robertson.   

Abstract

The concept that multiple system atrophy (MSA, Shy-Drager syndrome) is a disorder of the autonomic nervous system is several decades old. While there has been renewed interest in the movement disorder associated with MSA, two recent consensus statements confirm the centrality of the autonomic disorder to the diagnosis. Here, we reexamine the autonomic pathophysiology in MSA. Whereas MSA is often thought of as "autonomic failure", new evidence indicates substantial persistence of functioning sympathetic and parasympathetic nerves even in clinically advanced disease. These findings help explain some of the previously poorly understood features of MSA. Recognition that MSA entails persistent, constitutive autonomic tone requires a significant revision of our concepts of its diagnosis and therapy. We will review recent evidence bearing on autonomic tone in MSA and discuss their therapeutic implications, particularly in terms of the possible development of a bionic baroreflex for better control of blood pressure.

Entities:  

Keywords:  NASA Discipline Regulatory Physiology; Non-NASA Center

Mesh:

Year:  2002        PMID: 12127669     DOI: 10.1016/s0022-510x(02)00126-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Cevimeline hydrochloride improved cholinergic dysfunction in a patient with pure autonomic failure.

Authors:  Atsushi Ogata; Masayasu Kitano; Hajime Sano
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

2.  Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.

Authors:  Luis E Okamoto; Cyndya Shibao; Alfredo Gamboa; Leena Choi; André Diedrich; Satish R Raj; Bonnie K Black; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

Review 3.  Current concepts in orthostatic hypotension management.

Authors:  Amy C Arnold; Cyndya Shibao
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

Review 4.  Confounders of vasovagal syncope: orthostatic hypotension.

Authors:  Victor C Nwazue; Satish R Raj
Journal:  Cardiol Clin       Date:  2013-02       Impact factor: 2.213

Review 5.  Management approaches to hypertension in autonomic failure.

Authors:  Amy C Arnold; Italo Biaggioni
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-09       Impact factor: 2.894

6.  Anhidrosis in multiple system atrophy involves pre- and postganglionic sudomotor dysfunction.

Authors:  Elizabeth A Coon; Robert D Fealey; David M Sletten; Jay N Mandrekar; Eduardo E Benarroch; Paola Sandroni; Phillip A Low; Wolfgang Singer
Journal:  Mov Disord       Date:  2016-11-10       Impact factor: 10.338

7.  Evaluation of autonomic functions of patients with multiple system atrophy and Parkinson's disease by head-up tilt test.

Authors:  Chikako Watano; Yuri Shiota; Keiichi Onoda; Abdullah Md Sheikh; Seiji Mishima; Eri Nitta; Shozo Yano; Shuhei Yamaguchi; Atsushi Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-11-28       Impact factor: 3.575

Review 8.  The pathophysiology and diagnosis of orthostatic hypotension.

Authors:  David Robertson
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

9.  Clinical features and autonomic testing predict survival in multiple system atrophy.

Authors:  Elizabeth A Coon; David M Sletten; Mariana D Suarez; Jay N Mandrekar; J Eric Ahlskog; James H Bower; Joseph Y Matsumoto; Michael H Silber; Eduardo E Benarroch; Robert D Fealey; Paola Sandroni; Phillip A Low; Wolfgang Singer
Journal:  Brain       Date:  2015-09-13       Impact factor: 13.501

10.  Abnormal baroreceptor-mediated vasopressin release as possible marker in early diagnosis of multiple system atrophy.

Authors:  K Deguchi; I Sasaki; T Touge; M Tsukaguchi; H Takeuchi; S Kuriyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.